Longevity.Technology publishes report on atherosclerosis and Cyclarity’s novel approach


We invite you to read the Longevity.Technology report “Disease management to disease modification – removing plaque to undo atherosclerosis”.

This detailed report highlights:

  • Atherosclerosis disease profile – accounting for over 40% of all deaths worldwide.
  • Current treatments that fail to address the underlying cause of the disease, or reverse the atherosclerotic plaques already formed. 
    Cyclarity’s novel “disease-modifying” solution to repair an underlying cause of many age related diseases, removing toxic biomolecules from inside cells.
  • Cyclarity’s primary candidate, UDP-003 a beta-cyclodextrin designed to target and remove toxic, oxidized cholesterol.
  • The potential promise for investors, healthcare systems in the US and globally, and, most of all, for those affected by atherosclerosis-related disease.
The report concludes:

Cyclarity’s approach to true disease medication, and therefore reversal of age-related disease, without doubt, offers a great deal of promise for investors, for healthcare systems in the US and globally, and most of all for those affected by atherosclerosis-related disease.

. . . this may be the perfect opportunity for Cyclarity to enter the field, as it is one of the few solutions available that addresses the limiting factors of previous therapies both from a scientific perspective and from a market perspective.

We’re thrilled to be working towards reversing the world’s leading killer and thankful to Longevity.Technology for bringing a focus to our novel treatment.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.


Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.

Cyclarity News:

Cyclarity Therapeutics Announces Clinical Advisory Board

Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

Read More »

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Read More »